116 related articles for article (PubMed ID: 38199791)
1. DNA-PK-Mediated Cytoplasmic DNA Sensing Stimulates Glycolysis to Promote Lung Squamous Cell Carcinoma Malignancy and Chemoresistance.
Wang H; Zhang Y; Tian Y; Yang W; Wang Y; Hou H; Pan H; Pei S; Zhu H; Gu Z; Zhang Y; Dai D; Chen W; Zheng M; Luo Q; Xiao Y; Huang J
Cancer Res; 2024 Mar; 84(5):688-702. PubMed ID: 38199791
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma.
Castellano GM; Zeeshan S; Garbuzenko OB; Sabaawy HE; Malhotra J; Minko T; Pine SR
Mol Cancer Ther; 2022 Sep; 21(9):1381-1392. PubMed ID: 35732569
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma.
Shen C; Shyu DL; Xu M; Yang L; Webb A; Duan W; Williams TM
Mol Cancer Res; 2022 Mar; 20(3):425-433. PubMed ID: 34810212
[TBL] [Abstract][Full Text] [Related]
4. Knockdown of lysine (K)-specific demethylase 2B KDM2B inhibits glycolysis and induces autophagy in lung squamous cell carcinoma cells by regulating the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway.
Xie Z; Li H; Zang J
Bioengineered; 2021 Dec; 12(2):12227-12235. PubMed ID: 34783291
[TBL] [Abstract][Full Text] [Related]
5. The NRF2 antagonist ML385 inhibits PI3K-mTOR signaling and growth of lung squamous cell carcinoma cells.
Ji L; Moghal N; Zou X; Fang Y; Hu S; Wang Y; Tsao MS
Cancer Med; 2023 Mar; 12(5):5688-5702. PubMed ID: 36305267
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Glycolysis-Related Genes in Lung Squamous Cell Carcinoma.
Kadasah SF
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256214
[TBL] [Abstract][Full Text] [Related]
7. DNA damage repair gene signature model for predicting prognosis and chemotherapy outcomes in lung squamous cell carcinoma.
Wang X; Huang Z; Li L; Wang G; Dong L; Li Q; Yuan J; Li Y
BMC Cancer; 2022 Aug; 22(1):866. PubMed ID: 35941578
[TBL] [Abstract][Full Text] [Related]
8. Identification of a cancer-associated fibroblast classifier for predicting prognosis and therapeutic response in lung squamous cell carcinoma.
Lai X; Fu G; Du H; Xie Z; Lin S; Li Q; Lin K
Medicine (Baltimore); 2023 Sep; 102(38):e35005. PubMed ID: 37746966
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
Gong T; Cui L; Wang H; Wang H; Han N
J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
[TBL] [Abstract][Full Text] [Related]
10. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
11. GNA13 promotes the proliferation and migration of lung squamous cell carcinoma cells through regulating the PI3K/AKT signaling pathway.
Na J; Zhou W; Yin M; Hu Y; Ma X
Tissue Cell; 2022 Jun; 76():101795. PubMed ID: 35413491
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive molecular characterization of lung tumors implicates AKT and MYC signaling in adenocarcinoma to squamous cell transdifferentiation.
Quintanal-Villalonga A; Taniguchi H; Zhan YA; Hasan MM; Chavan SS; Meng F; Uddin F; Allaj V; Manoj P; Shah NS; Chan JM; Ciampricotti M; Chow A; Offin M; Ray-Kirton J; Egger JD; Bhanot UK; Linkov I; Asher M; Roehrl MH; Ventura K; Qiu J; de Stanchina E; Chang JC; Rekhtman N; Houck-Loomis B; Koche RP; Yu HA; Sen T; Rudin CM
J Hematol Oncol; 2021 Oct; 14(1):170. PubMed ID: 34656143
[TBL] [Abstract][Full Text] [Related]
13. LINC01936 inhibits the proliferation and metastasis of lung squamous cell carcinoma probably by EMT signaling and immune infiltration.
Tian Q; Liu X; Li A; Wu H; Xie Y; Zhang H; Wu F; Chen Y; Bai C; Zhang X
PeerJ; 2023; 11():e16447. PubMed ID: 38084139
[TBL] [Abstract][Full Text] [Related]
14. circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.
Gao W; Guo H; Niu M; Zheng X; Zhang Y; Xue X; Bo Y; Guan X; Li Z; Guo Y; He L; Zhang Y; Li L; Cao J; Wu Y
Mol Cancer; 2020 Nov; 19(1):166. PubMed ID: 33234130
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol improves the cytotoxic effect of CD8 +T cells in the tumor microenvironment by regulating HMMR/Ferroptosis in lung squamous cell carcinoma.
Shan G; Minchao K; Jizhao W; Rui Z; Guangjian Z; Jin Z; Meihe L
J Pharm Biomed Anal; 2023 May; 229():115346. PubMed ID: 37001272
[TBL] [Abstract][Full Text] [Related]
16. Involvement of CHRNA6 in the Immune Response in Lung Squamous Cell Carcinoma and its Potential as a Drug Target for the Disease.
Zhang F; Zhang M; Yuan X; Tao Y; Wang J
Curr Pharm Des; 2023; 29(26):2091-2100. PubMed ID: 37680128
[TBL] [Abstract][Full Text] [Related]
17. A glycolysis-based three-gene signature predicts survival in patients with lung squamous cell carcinoma.
Huang G; Zhang J; Gong L; Huang Y; Liu D
BMC Cancer; 2021 May; 21(1):626. PubMed ID: 34044809
[TBL] [Abstract][Full Text] [Related]
18. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis.
Zhang LX; Gao J; Long X; Zhang PF; Yang X; Zhu SQ; Pei X; Qiu BQ; Chen SW; Lu F; Lin K; Xu JJ; Wu YB
Mol Cancer; 2022 May; 21(1):110. PubMed ID: 35525959
[TBL] [Abstract][Full Text] [Related]
19. Immune signature of T follicular helper cells predicts clinical prognostic and therapeutic impact in lung squamous cell carcinoma.
Xu F; Zhang H; Chen J; Lin L; Chen Y
Int Immunopharmacol; 2020 Apr; 81():105932. PubMed ID: 31836430
[TBL] [Abstract][Full Text] [Related]
20. Deciphering a cell death-associated signature for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma.
Mao G; Yang D; Liu B; Zhang Y; Ma S; Dai S; Wang G; Tang W; Lu H; Cai S; Zhu J; Yang H
Respir Res; 2023 Jul; 24(1):176. PubMed ID: 37415224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
